Guidelines Developed to Improve Newborn Screening for Cystic Fibrosis

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 18, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, April 18, 2025 -- In a guideline issued by the U.S. Cystic Fibrosis Foundation and published online April 2 in the International Journal of Neonatal Screening, recommendations are presented to improve sensitivity, equity, and timeliness of cystic fibrosis (CF) screening in newborns.

Meghan E. McGarry, M.D., from the University of Washington School of Medicine in Seattle, and colleagues developed recommendations for newborn screening program practices to improve the diagnosis of infants with CF.

The authors developed seven recommendations for newborn screening practices. Use of a floating immunoreactive trypsinogen (IRT) cutoff is recommended over a fixed IRT cutoff. In CF newborn screening programs with variant panels that do not include all CF-causing variants in CFTR2 or variant panels that do not achieve at least 95 percent sensitivity in all ancestral groups within the state, a very high IRT referral strategy is recommended. CF newborn screening algorithms should not limit CFTR variant detection to the F508del variant or variants included in the American College of Medical Genetics-23 panel. Screening programs should screen for all CF-causing CFTR variants in CFTR2. CFTR variant screening is recommended twice a week or more frequently as resources allow. To improve the specificity and positive predictive value of CF newborn screening, a CFTR sequencing tier should be included following IRT and CFTR variant panel testing. Both the primary care provider and CF specialist should be notified of abnormal newborn screening results.

"Newborn screening programs have allowed for early diagnosis, improved monitoring, and early treatment for most infants with CF," the authors write. "It is crucial for programs to engage in continued process improvement to ensure that all infants with CF benefit from timely and accurate identification."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-19 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords